JP2024508045A5 - - Google Patents

Info

Publication number
JP2024508045A5
JP2024508045A5 JP2023571435A JP2023571435A JP2024508045A5 JP 2024508045 A5 JP2024508045 A5 JP 2024508045A5 JP 2023571435 A JP2023571435 A JP 2023571435A JP 2023571435 A JP2023571435 A JP 2023571435A JP 2024508045 A5 JP2024508045 A5 JP 2024508045A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
group
cancer
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/013725 external-priority patent/WO2022164812A1/en
Publication of JP2024508045A publication Critical patent/JP2024508045A/ja
Publication of JP2024508045A5 publication Critical patent/JP2024508045A5/ja
Pending legal-status Critical Current

Links

JP2023571435A 2021-02-01 2022-01-25 ホスホイノシチド3キナーゼベータ阻害剤ならびにそれらの組成物および方法 Pending JP2024508045A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144287P 2021-02-01 2021-02-01
US63/144,287 2021-02-01
PCT/US2022/013725 WO2022164812A1 (en) 2021-02-01 2022-01-25 Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2024508045A JP2024508045A (ja) 2024-02-21
JP2024508045A5 true JP2024508045A5 (cg-RX-API-DMAC7.html) 2025-01-21

Family

ID=82654889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571435A Pending JP2024508045A (ja) 2021-02-01 2022-01-25 ホスホイノシチド3キナーゼベータ阻害剤ならびにそれらの組成物および方法

Country Status (9)

Country Link
US (1) US20240166617A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284375A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024508045A (cg-RX-API-DMAC7.html)
KR (1) KR20240016938A (cg-RX-API-DMAC7.html)
CN (1) CN117615763A (cg-RX-API-DMAC7.html)
AU (1) AU2022214080A1 (cg-RX-API-DMAC7.html)
CA (1) CA3209581A1 (cg-RX-API-DMAC7.html)
IL (1) IL304895A (cg-RX-API-DMAC7.html)
WO (1) WO2022164812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217937A1 (en) 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2023013987A (es) 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20260130925A1 (en) * 2022-10-14 2026-05-14 Genesis Molecular Ai, Inc. Methods for treating cancer
EP4602043A1 (en) * 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
EP4680612A1 (en) * 2023-03-15 2026-01-21 AN2 Therapeutics, Inc. Chemical compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363471T1 (de) * 2000-01-24 2007-06-15 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
EP1537102A4 (en) * 2002-08-16 2010-12-08 Astrazeneca Ab INHIBITORS OF PHOSPHOINOSITIDE-3-KINASE BETA
WO2008148074A2 (en) * 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Similar Documents

Publication Publication Date Title
TWI765451B (zh) 作為erk抑制劑的螺環類化合物及其應用
US20220204507A1 (en) Nitrogen-containing spiro derivative as ret inhibitor
JP2025114615A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
US8026271B2 (en) Formulations of indol-3-yl-2-oxoacetamide compounds
CN101945876B (zh) 对慢性疼痛疾病有活性的含氮双环化合物
US20240050401A1 (en) Methods of treating social function disorders
JP2004520285A5 (cg-RX-API-DMAC7.html)
JP2018524339A5 (cg-RX-API-DMAC7.html)
KR102866223B1 (ko) 피롤로피리미딘 화합물 및 그 용도
US8704001B2 (en) Deuterated 2-amino-3-hydroxypropanoic acid derivatives
JP2022543666A5 (cg-RX-API-DMAC7.html)
RU2008119651A (ru) Производные дикарбоновых кислот и их применение
JP2020511547A5 (cg-RX-API-DMAC7.html)
JP2023528073A (ja) Gpr65モジュレーターとしてのn-フェニルアミノカルボニル、ピリジノ-、ピリミジノ及びベンゾトロパン
WO2022247757A1 (zh) 氟取代的嘧啶并吡啶类化合物及其应用
RU2018103332A (ru) Пиримидиновое соединение с конденсированными кольцами, его промежуточное соединение, способ получения, композиция и применение
JP2024524312A (ja) アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用
JP2022529309A5 (cg-RX-API-DMAC7.html)
TW201231055A (en) Novel medicament combinations for the treatment of respiratory diseases
JP2024542881A5 (cg-RX-API-DMAC7.html)
US20190343827A1 (en) Deuterated analogs of tariquidar
KR101288791B1 (ko) 베타 효능제의 흡입용 에어로졸 제형
WO2025227943A1 (zh) 作为GSPTs/CK1α双靶降解剂的新型取代杂环类化合物
JP2023503672A (ja) 縮合ピリジン環誘導体、その調製方法及びその医薬的応用
ES2677714T3 (es) Nueva forma polimórfica de un agonista del adrenorreceptor beta-2 de acción prolongada